From the Guidelines

Meloxicam (Mobic) is effective for reducing pain and inflammation.

Meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), has been shown to be effective in reducing pain and inflammation in various clinical settings, including postoperative pain management and osteoarthritis treatment 1.
Studies have demonstrated that meloxicam is as effective as other NSAIDs, such as ibuprofen and naproxen, in reducing pain and inflammation, with a similar safety profile 1.
Meloxicam has been specifically recommended for use as a preemptive medication for postoperative pain management, particularly for abdominal hysterectomy patients, due to its effectiveness in reducing pain and total narcotic consumption 1.
The evidence suggests that meloxicam is a viable option for patients who require pain management, particularly those with osteoarthritis or postoperative pain, with a favorable risk-benefit profile compared to other NSAIDs and COX-2 inhibitors 1.

The recommended dosage of meloxicam varies depending on the specific clinical setting and patient population, but typical dosages range from 7.5 to 15 mg per day 1.
Meloxicam can be administered orally or intravenously, with oral administration being the most common route of administration 1.

From the Research

Meloxicam has been shown to be effective in the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute 'rheumatic' pain 2, 3, 4, 5, 6
Clinical trials have demonstrated that meloxicam is as effective as other NSAIDs, such as piroxicam, diclofenac, and naproxen, in reducing pain and inflammation 2, 4, 5, 6
Meloxicam has been found to have a favorable therapeutic ratio, with anti-inflammatory effects similar to or better than those of other NSAIDs, and a lower risk of gastrointestinal adverse effects 3, 4, 6

Meloxicam has been shown to have improved gastrointestinal tolerability compared to non-selective NSAIDs, with less clinical gastrointestinal symptoms and less perforations, obstructions, and bleeds 2, 4, 5
Studies have demonstrated that meloxicam causes less endoscopically detected gastrointestinal damage and fewer peptic ulcers and GI bleeds than other NSAIDs, such as piroxicam, diclofenac, and naproxen 4, 6
The COX-2 preferential activity of meloxicam is thought to contribute to its lower gastrointestinal toxicity compared to non-selective NSAIDs 2, 3, 5

Meloxicam has been found to have a similar rate of adverse events, including peripheral oedema and hypertension, compared to traditional NSAIDs 2
The renal safety profile and incidence of liver function abnormalities with meloxicam are equivalent to other NSAIDs available for clinical use 4
Meloxicam has been shown to be well tolerated in clinical trials, with a favorable safety profile compared to other NSAIDs 3, 5, 6